(VIANEWS) – WEBSTEP (WSTEP.OL), SPBK1 HELGELAND (HELG.OL), TUBIZE-FIN (TUB.BR) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up until now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. WEBSTEP (WSTEP.OL)
120.57% Payout Ratio
Webstep ASA, together with its subsidiaries, provides information technology (IT) consultancy services to public and private businesses in Norway and Sweden. The company offers digitalization, cloud migration and integration, Internet of Things, machine learning, IT security, robotics, and analytics. Its services include consulting, digitalization, .Net, Java, open source, full stack, front and back end, user experience, integration, mobility, cloud apps, machine learning, business intelligence, big data, data warehousing, virtual robotics, Devops, application service management, and data science services; and cloud computing, cloud services, integration, sensor technology, product and service development, Beacons, enterprise user experience, web analysis, design team, Amazon Web, Azure, prediction, AI, mobility predictive modelling, predictive modelling, hackathon, business analysis, and search engine optimization services. The company serves banking, finance and insurance, public administration, agriculture and food production, IT and telecommunication, commerce, and transportation industries. The company was founded in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, WEBSTEP has a trailing twelve months EPS of kr1.41.
PE Ratio
WEBSTEP has a trailing twelve months price to earnings ratio of 20.78. Meaning, the purchaser of the share is investing kr20.78 for every norwegian krone of annual earnings.
More news about WEBSTEP.
2. SPBK1 HELGELAND (HELG.OL)
75.44% Payout Ratio
SpareBank 1 Helgeland provides various financial products and services to retail customers, small and medium enterprises, municipal authorities, and institutions in Norway. The company operates in two segments, Retail Market and Corporate Market. It offers savings, investment, and insurance products, as well as leasing and mortgage services. The company is also involved in owning, managing, and letting commercial properties. It operates through branches located in Mosjøen, Brønnøysund, and Sandnessjøen. The company was founded in 1860 and is headquartered in Mo i Rana, Norway.
Earnings Per Share
As for profitability, SPBK1 HELGELAND has a trailing twelve months EPS of kr13.71.
PE Ratio
SPBK1 HELGELAND has a trailing twelve months price to earnings ratio of 8.9. Meaning, the purchaser of the share is investing kr8.9 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.14%.
Moving Average
SPBK1 HELGELAND’s value is below its 50-day moving average of kr124.54 and higher than its 200-day moving average of kr119.93.
More news about SPBK1 HELGELAND.
3. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.92.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 36.41. Meaning, the purchaser of the share is investing €36.41 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Moving Average
TUBIZE-FIN’s worth is below its 50-day moving average of €75.27 and under its 200-day moving average of €72.80.
More news about TUBIZE-FIN.
4. HYDRATEC (HYDRA.AS)
37.84% Payout Ratio
Hydratec Industries NV, through its subsidiaries, engages in the manufacture and sale of industrial systems and plastic components for food, health, and mobility markets in the Netherlands, rest of Europe, Asia, North America, South America, Africa, and Oceania. It develops and produces sterilized product handling systems; and automated packaging solutions, including packaging for sterilized food in pouches, tins, and jars, as well as main-meal salads and agri-food in bags, nets, boxes, and crates. The company also supplies industrial incubators to produce day-old chicks; hatchery automation systems for processing of hatchery eggs and day-old chicks; climate control equipment for air and water treatment; hatchery management software for monitoring, analyzing, and optimizing the hatching process; and service and support for hatchery systems operation. In addition, it manufactures extrusion machines for PVC, PVC-O, and PO pipes; plastic injection molding products for use in climate control systems, lorries, bicycle parts, and coffee machines; rubber and plastic precision components for fuel systems, braking and drive systems, dosing systems for beer, coffee and milk, medical cartridges, point-of-care instruments, and diagnosis equipment. Hydratec Industries NV is headquartered in Amersfoort, the Netherlands.
Earnings Per Share
As for profitability, HYDRATEC has a trailing twelve months EPS of €12.22.
PE Ratio
HYDRATEC has a trailing twelve months price to earnings ratio of 6.91. Meaning, the purchaser of the share is investing €6.91 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.49%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.8%, now sitting on 283.26M for the twelve trailing months.
More news about HYDRATEC.
